Abstract
Regulatory authorities have approved several polyethylene glycol (PEG)–conjugated biological drugs and many more are currently in clinical trials. Biosimilars and follow-on versions of previously approved PEG conjugates are also gaining approval. PEG size in approved drugs ranges from 5 to 60kDa, with different sizes of PEG reagents, different coupling chemistries, different PEG architectures, and different strategies for PEG placement reflecting the balance between ideality and commercial practicality. While many PEGylated protein reviews exist, this article focuses on why a given PEGylation strategy solves a problem by addressing a specific clearance mechanism or favorably improves biodistribution compared to the native molecule.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
